Antonio Ortiz Buijsse
Overview
Explore the profile of Antonio Ortiz Buijsse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Overdijk M, Strumane K, Beurskens F, Ortiz Buijsse A, Vermot-Desroches C, Vuillermoz B, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2126-2138.
PMID: 32847982
Higher-order death receptor 5 (DR5) clustering can induce tumor cell death; however, therapeutic compounds targeting DR5 have achieved limited clinical efficacy. We describe HexaBody-DR5/DR5, an equimolar mixture of two DR5-specific...
2.
Overdijk M, Verploegen S, Ortiz Buijsse A, Vink T, Leusen J, Bleeker W, et al.
J Immunol
. 2012 Sep;
189(7):3430-8.
PMID: 22956577
Development of human therapeutic Abs has led to reduced immunogenicity and optimal interactions with the human immune system in patients. Humanization had as a consequence that efficacy studies performed in...
3.
Labrijn A, Ortiz Buijsse A, van den Bremer E, Verwilligen A, Bleeker W, Thorpe S, et al.
Nat Biotechnol
. 2009 Jul;
27(8):767-71.
PMID: 19620983
Two humanized IgG4 antibodies, natalizumab and gemtuzumab, are approved for human use, and several others, like TGN1412, are or have been in clinical development. Although IgG4 antibodies can dynamically exchange...